ABK Biomedical Raises USD 30M in Series C Financing

Funding supports Eye90 microspheres® FDA IDE approval toward U.S. pivotal study execution and ongoing clinical operations

Research and Development

Watch an animated overview of the Eye90 microspheres® Administration Procedure and learn about the potential for our technology to improve outcomes for patients with liver tumors

ABK Biomedical

Improving treatment options for patients with hypervascular liver tumors

Scientific Excellence


ABK-affiliated researchers regularly present and publish new data and findings at top international conferences and in peer-reviewed journals.

Visit our Scientific Research Portal to learn more about the promise of Eye90 microspheres Precision Dosimetry™ for patients with liver cancers.

Watch how we are developing glass microsphere technologies to treat cancer

Latest News

December 6th 2022

ABK Biomedical Raises USD 30M in Series C Funding

Go to the Press Release»»

September 12th 2022

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

Go to the Press Release»»

September 12th 2022

ABK Biomedical announces the appointment of Dr. Aravind Arepally as Chief Medical Officer effective, September 12th 2022

Meet Our New CMO»»

April 19th 2022

ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors

Go to the Press Release»»

Meet Our New CMO

ABK Biomedical announces the appointment of Dr. Aravind Arepally to the newly created full-time position of Chief Medical Officer effective, September 12th, 2022.

Aravind joins ABK with extensive clinical experience in Interventional Oncology, Y90 procedures, and the medical device industry. Aravind obtained his medical degree and completed his radiology residency at Emory University in Atlanta. After finishing his fellowship at Johns Hopkins Medical Institutes, he joined the faculty, becoming an Associate Professor of Radiology and Surgery. Aravind eventually moved back to Atlanta as a practicing physician in private practice, becoming the Chair of Radiology, Section Chief of IR, and a member of the Board of Directors at Radiology Associates of Atlanta at Piedmont Hospital. He is also currently an Adjunct Professor of Radiology at Vanderbilt University School of Medicine.

In the area of medical technology development, Aravind co-founded Surefire Medical in 2010 where he was Chief Scientific Officer and spent 10 years guiding pre-clinical research, global clinical trials/strategy, and FDA interactions. Surefire (now TriSalus Life Sciences) is now commercially available in US, Europe, Asia, and South America. Additional prior industry experience includes time as a Visiting Clinical Scientist with Siemen’s Healthcare focusing on molecular imaging and image guided therapies. Most recently, Aravind left full-time clinical practice and was appointed Senior Director of R&D for Varian, Siemens Healthineers.

Aravind has received numerous NIH Grants and completed several human clinical trials in the areas of Imaging, Medical Devices, and embolotherapies. He is an author on over 150 publications, numerous medical textbooks, and has been part of faculty and lectures at over 100 conferences in his career. He has extensive teaching and mentoring experience and has consulted for many companies in the Interventional Radiology and Oncology space. He is a widely respected Key Opinion Leader in Interventional Medicine and has performed over 500 Yttrium 90 procedures in his career. His unique combination of industry, start-up, imaging, radiology, and oncology experience make him uniquely suited as the Chief Medical Officer at ABK Biomedical Inc.


Aravind Arepally, MD., Chief Medical Officer

Company News & Press Releases

ABK and University of Missouri Veterinary Health Center partner on new Y90 liver cancer trial for dogs

Halifax, Nova Scotia. March 7th, 2021. ABK Biomedical today announced that they entered into a partnership with…

Read about the study»»

ABK Biomedical partners with the CNIC to enhance patient care

Halifax, Nova Scotia. March 3rd 2020. ABK Biomedical, which is developing a transformative Eye90 microspheres® technology, with the potential to provide in-procedure prognostic dosimetry

Read the Press Release»»

ABK Biomedical Inc. Raises $30M USD in Series B Financing

Halifax, Nova Scotia. April 8th, 2019. ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing…

Read the Press Release»»

Strategic Partnership with the University of Missouri Research Reactor Center (MURR®)

Halifax, Nova Scotia. February 13th, 2019. ABK Biomedical Inc. (ABK) is pleased to announce a multi-year strategic partnership with the University of Missouri Research Reactor Center (MURR®)…

Read the Press Release»»

Our Products

Eye90 microspheres logo

Eye90 microspheres®

A novel technology for Y90 radioembolization made with a proprietary, radiopaque glass composition for in-procedure visualization.

Bland embolization with easi-vue embolic microspheres

Easi-Vue™ embolic microspheres

Radiopaque bland embolization product allowing direct visualization at the target site. FDA 510(k) clearance for the embolization of arteriovenous malformations and hypervascular tumors.

Leadership Team

Mike Mangano - President and CEO ABK Biomedical

Michael Mangano

President and CEO

> an accomplished global executive leader with over 25 years’ experience in the medical device industry. 

Gary - Donofrio - Chief Business Officer ABK Biomedical

Gary Donofrio

Chief Business Officer

> extensive marketing and commercialization experience with over 25 years in the medical device field.

Mike Tyson - CFO ABK Biomedical

Mike Tyson

Chief Financial Officer

> over 35 years’ experience in public accounting and leadership positions.

Mike Tyson - CFO ABK Biomedical

Aravind Arepally

Chief Medical Officer

> Chief Medical Officer and practicing Interventional Radiologist with extensive industry and academic experience.

David Dobrowski - VP Clinical Development ABK biomedical

David Dobrowski

VP of Clinical Development and Regulatory Affairs

> an accomplished Life Sciences Executive and Enterprise Leader with over 25 years of pharmaceutical and medical device development experience. 

Marc Gregoire - VP R&D ABK Biomedical

Mark Gregoire

VP R&D and Nuclear Operations

> an accomplished professional mechanical engineer with extensive experience in the nuclear medical products sector.

Anthony Headley - VP Manufacturing ABK Biomedical

Anthony Headley

Vice President, Manufacturing and Facilities

> an accomplished medical device executive with 25 years experience leading and building engineering, manufacturing, and R&D organizations


The ABK Biomedical Team

We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.

ABK Biomedical is an equal opportunity employer offering competitive compensation packages.

ABK's Business Partners

ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.

Research Partners

Development Partners

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3

T. 902.442.4009


Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.

Copyright 2022 - All International Rights Reserved